The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

Item

http://www.wikidata.org/entity/Q28200492

Q28200492

about

New Therapeutic Approaches in Polycythemia Vera Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management Refractory anemia with ring sideroblasts and RARS with thrombocytosis JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.Coagulation changes during presyncope and recovery.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Platelet counts and platelet activation markers in obese subjects.Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.Acute compartment syndrome as the initial manifestation of chronic-phase chronic myeloid leukemia: a case report and review of the literature Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice.JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.Anagrelide: 20 years later.Pathophysiology of acquired von Willebrand disease: a concise review.Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.Polycythemia vera: current pharmacotherapy and future directions.Bone morbidity in chronic myeloproliferative neoplasms.Treatment of the acquired von Willebrand syndrome.Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices.Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm Essential thrombocytosis accompanied by coagulation factor XII deficiency: a case report.Characterisation of changes in the haemostasis system in dogs with thrombosis.In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.Thrombocytosis in 715 Dogs (2011-2015).Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case-control study.Clinical and laboratory assessment of a patient with thrombocytosis.

P2860

Q26795677-6C07F4AF-A393-48A3-84E9-554EBE200614 Q26851894-19BCC815-9BB2-419E-86F6-3299888A29BB Q28083238-E9A1A0CF-52CA-4FDB-A5F2-5E74692D37C7 Q30572002-533E3166-2FE5-40CC-A711-F045A540F5AF Q33161632-56ADADD8-8C5A-4D00-A311-6FC9149806B5 Q34166859-B10F41A6-3612-4CFB-8FA8-B5C6F3F61AEA Q36513046-7519A47F-BACF-46B1-94B9-3CF840B3F08B Q36654317-4BC18017-5690-4783-8E7E-92CE1F2DE326 Q37118063-71323807-EE5A-4D52-B12C-F6E7028FEF68 Q37328478-EC8686B6-3065-4267-BC0A-FE8E51DEA83B Q37349414-F7155FE9-1A62-452C-A39A-A9E48CD648EA Q37357291-C60FFED9-04CF-4E2B-995C-425B7EFA38FB Q37870983-32A38FCC-1861-4056-A2D7-7CF2D0452164 Q37983791-B325675E-93BC-4314-86CB-2FC897393C01 Q38088262-5344F97C-2A8A-4A48-9DD0-35E2AD2BFA55 Q38513219-878809AF-1B55-49DF-8691-ADCE5CC082E3 Q38636087-68F3463D-AFAC-4636-BFAF-90A0E3EB496E Q39041471-24CBF596-C15A-45A2-966C-5169C9F16BCA Q39131365-83A3D005-B744-460F-85C8-3EB4E5CCE1D3 Q39282205-A5C2F36D-8218-4FCC-BCA7-D9CB8C09F5EF Q41646222-E644F5D3-6B4A-4A3C-BAED-B5AE8054738C Q42189605-542670A7-153E-44D6-94BF-A50FB0418735 Q42576077-FA1C427E-B5F9-4AEB-A049-748AC0F2638B Q44007754-EA84D3E4-6DFB-43B1-B677-49BF549F8D1C Q46113374-FD225AF3-C8FA-459B-A8B3-542CEABE6264 Q46113435-CA1371BA-7FDA-41C3-BECC-2D8C580539BC Q47168276-697C744A-F556-4E46-9232-AAE691633EA9 Q47294481-78B48A56-96A4-47DF-8946-7069D3D9CD40 Q47741741-73906E68-39A1-445B-B805-46CB1711D026 Q50093425-0DE05774-F484-4488-A5E6-EEFAC922DAC1

P2860

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

Item

http://www.wikidata.org/entity/Q28200492

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu